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Summary
This work describes a flexible technique for the analysis of protein sequences as a source
of motifs affecting bodily functions. The BIOPEP database, along with the Pôle Bioinfor-
matique Lyonnais (PBIL) server, were applied to define which activities of peptides dom-
inated in their protein precursors and which structure of the protein contained the most of
the revealed activities. Such an approach could be helpful in finding some structural requi-
rements for peptide(s) to be regarded as biologically active (bioactive). It was found that
apart from the activities of peptides that commonly occur in the majority of proteins (e.g.
ACE inhibitors), all analyzed proteins can be a source of motifs involved in e.g. activation
of ubiquitin-mediated proteolysis. This could be important in designing diets for patients
who suffer from neural diseases. The structure and bioactivity analyses revealed that if
peptides were to be 'bioactive', it is essential that they assume the position of a coil (or
combination of coil and a-helix) in the sequence of their protein precursors. However, it is
recommended to consider the factors such as the length of peptide chains, the number of
peptides in the database as well as the repeatability of the occurrence of characteristic ami-
no acids, both in the peptide and in the protein when studying the bioactivity and structu-
re of biomolecules.
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Introduction
Food-derived bioactive proteins are considered to be
components that reduce the risk of disease or enhance a
certain physiological function (1). Peptides encrypted in
the protein molecules are believed to attribute the physi-
cochemical and sensory functions to proteins, which are
also regarded as functional and health-promoting ingre-
dients. There are many activities of peptides described
in the literature, e.g. antioxidative, antimicrobial, antithrom-
botic, opioid or immunomodulating as well as the inhi-
bition of ACE (EC 3.4.15.1), involved in blood pressure
reduction (2). Data concerning the peptide activities are
often available in databases, e.g. BIOPEP, SwePep, or
ANTIMIC (3). Such databases are interconnected with
other computer resources that allow for the identifica-
tion of protein function based on its secondary structure
prediction (4), homology level (5) or topological features
(6). According to Blythe et al. (7) databases are the lingua
franca of bioinformatics – a discipline created to un-
derstand the biological processes by applying specially
designed mathematical and statistical algorithms com-
bined with information technology (8).
The properties of molecules, including peptides, are
described by their structure as well as physicochemical
or pharmacological attributes defined as descriptors. They
can be computed based on the structure of the molecule,
e.g. molecular mass, charge, solubility (molecular de-
scriptors) or derived by means of multivariate statistics
(pharmacological descriptors) (9). These descriptors (if ex-
pressed in numbers) are applicable in the QSAR (quan-
titative structure–activity relationship) approach, which
can be described as the mathematical function:
P=f(x1, x2,…xn) /1/
where P means molecular property (activity) of a mole-
cule and x1, x2,…xn are the n molecular descriptors (10).
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The above-mentioned technique has successfully been ap-
plied in drug design, bioactivity prediction and biolog-
ical response of chemical compounds (11). In food science,
QSAR is used as a method to discover the relationships
between the structure and activity of ACE inhibitors and
bitter taste peptides when, in both cases, hydrophobicity
was the main factor affecting the activity of peptides (12,
13).
The protein sequence can also be evaluated as a
good/bad precursor of peptides with biological activity
(14). Such an evaluation can be performed by the appli-
cation of discriminants developed by Dziuba and Iwa-
niak (15). They are available in the BIOPEP database (16).
It is well-known that the activity of peptide depends on
its amino acid composition and structure (17). Due to
the fact that the sequences of bioactive peptides can be
easily retrieved from any database, this study focuses on
the activities of peptides that dominate in the proteins
and the structure of the protein that is the most 'friendly'
for acquiring the most of the revealed activities. Such an
approach could be helpful in finding some structural re-
quirements for peptides, which are regarded as biologi-
cally active (bioactive).
Materials and Methods
The detailed procedure of data selection and analy-
sis is shown in Fig. 1. Briefly, twenty sequences of food
proteins were taken from the BIOPEP database (bar named
'Proteins') at www.uwm.edu.pl/biochemia (16,18). These pro-
teins represent food components which are commonly
consumed by the population, i.e. milk, meat, fish, egg,
crops, seeds and leguminous plants. The full names of
the analyzed proteins are shown in Fig. 2. To find the
bioactivities occurring in the above-mentioned proteins,
discriminant A was calculated, which is defined as the
occurrence frequency of the fragments with a given activ-






where a is the number of fragments with given activity
in the protein chain, and N is the number of amino acid
residues in the protein molecule (19).
The secondary structures of proteins were predicted
by the use of GOR1 algorithm available at Pôle Bioinfor-
matique Lyonnais (PBIL) server (20). Pôle Bioinformatique
Lyonnais provides many tools to analyze protein and pep-
tide sequences. It is helpful to predict e.g. the secondary
structures of a protein based on its amino acid compo-
sition (21).
The last stage of the studies (see 'Results' in Fig. 1)
was to identify particular sequences of bioactive fragments
with their locations in the protein. It was performed by
running the function called 'profile of the potential bio-
logical activity of proteins', i.e. type and location of bio-
active fragments in a protein chain (19). Based on the
match of the peptide(s) to the appropriate secondary struc-
ture(s) present in the protein, it was then possible to try
to find some structural requirements for motifs to be de-
fined as bioactive.
Although the profiles of potential biological activity
were performed for all protein sequences, this paper pre-
sents only one of them generated for carp (Cyprinus car-
pio) parvalbumin (Table 1). Both the profile of potential
biological activity of a protein and the frequency of occur-
rence of fragments with a given activity are the equi-
valent criteria of protein evaluation in the context of being
a good or bad source of biopeptides (19).
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Fig. 1. Data analysis procedure combining BIOPEP database and Pôle Bioinformatique Lyonnais server
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Fig. 2. Distribution of the secondary structures in protein chains using the Pôle Bioinformatique Lyonnais server
blue – a-helix, red – extended strand, violet – random coil
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Fig. 2. – continued: blue – a-helix, red – extended strand, violet – random coil
Results and Discussion
The values of frequency of the occurrence of frag-
ments with the given activity (A) for all analyzed sequen-
ces are shown in Table 2. Nineteen biological activities
can be distinguished in the protein sequences taken for
the analysis. Six of them, i.e. antibacterial, coeliac-toxic,
chemotactic, contracting smooth muscles, neuropeptide
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Table 1. An example of the biological activities revealed in the peptide profile of carp (Cyprinus carpio) parvalbumin. Analysis per-
formed by the use of BIOPEP database
Activity Sequence and its location in a protein chain
ACE inhibitor LKL [64-66]; LF [66-67]; VK [107-108]; LKA [87-89]; AF [2-3],[47-48],[85-86];
RA [76-77]; AA [14-15],[21-22],[104-105]; GF [57-58]; VG [34-35]; IG [98-99];
GI [5-6]; GA [74-75]; GL [35-36]; AG [4-5],[73-74],[89-90]; DA [9-10],[80-81];
GV [99-100]; GK [96-97]; QG [17-18]; SG [56-57]; GD [90-91],[94-95]; DG [93-94],
[95-96]; NF [70-71]; SF [24-25],[29-30]; KL [65-66]; YK [27-28]; AR [75-76];
KA [46-47],[84-85],[88-89],[108-109]; IE [59-60]; LQ [16-17],[68-69]; LN [7-8]
Dipeptidyl peptidase-IV inhibitor MA [1-2]; KA [46-47],[84-85],[88-89],[108-109]; FA [3-4],[31-32],[48-49],[103-104]
Bacterial permease ligand KK [45-46]
Regulation of ion flow DY [26-27]
Activation of ubiquitin-mediated proteolysis RA [76-77]




aS1-casein/0.462; b-casein/0.545; a-lactalbumin/0.317; b-lactoglobulin/0.421; k-casein/0.363; myosin/0.395;
a1-collagen/0.874; troponin C/0.375; carp parvalbumin/0.404; salmon b1-parvalbumin/0.376; egg-white
cystatin/0.302; egg ovalbumin/0.340; a/b-gliadin precursor/0.29; a-hordothionin precursor/0.315; 12S seed
storage globulin precursor/0.315; 7S globulin precursor/0.315; 11S cruciferin/0.356; phaseolin, b-type/0.312;




aS1-casein/0.005; a-lactalbumin/0.007; b-lactoglobulin/0.022; k-casein/0.005; myosin/0.011; a1-collagen/0.874;
troponin C/0.019; carp parvalbumin/0.009; egg-white cystatin/0.022; egg ovalbumin/0.008; a/b-gliadin
precursor/0.012; a-hordothionin precursor/0.016; 12S seed storage globulin precursor/0.315; 7S globulin
precursor/0.012; 11S cruciferin/0.014; phaseolin, b-type/0.010; vicilin/0.009; legumin B chain/0.018 total=18
Antiamnestic aS1-casein/0.005; b-casein/0.043; a1-collagen/0.267; egg ovalbumin/0.003; a/b-gliadin precursor/0.004;
12S seed storage globulin precursor/0.006; 7S globulin precursor/0.006; 11S cruciferin/0.006; phaseolin,
b-type/0.002; vicilin/0.070; legumin B chain/0.003 total=11
Antioxidative aS1-casein/0.005; b-casein/0.014; a-lactalbumin/0.007; k-casein/0.032; salmon b1-parvalbumin/0.009; egg
ovalbumin/0.008; a/b-gliadin precursor/0.008; 12S seed storage globulin precursor/0.006; 7S globulin
precursor/0.006; phaseolin, b-type/0.005; vicilin/0.002 total=11
Antithrombotic b-casein/0.029; k-casein/0.021; a1-collagen/0.298; egg ovalbumin/0.003; 12S seed storage globulin
precursor/0.006; 7S globulin precursor/0.006; 11S cruciferin/0.006; phaseolin, b-type/0.002; vicilin/0.007;
legumin B chain/0.331 total=10
Bacterial permease
ligand
aS1-casein/0.005; b-casein/0.005; a-lactalbumin/0.007; b-lactoglobulin/0.012; k-casein/0.005; myosin/0.016;









aS1-casein/0.069; b-casein/0.148; a-lactalbumin/0.042; b-lactoglobulin/0.090; k-casein/0.089; myosin/0.112;
a1-collagen/0.268; troponin C/0.025; carp parvalbumin/0.083; salmon b1-parvalbumin/0.073; egg-white
cystatin/0.094; egg ovalbumin/0.049; a/b-gliadin precursor/0.072; a-hordothionin precursor/0.024; 12S seed
storage globulin precursor/0.075; 7S globulin precursor/0.075; 11S cruciferin/0.086; phaseolin, b-type/0.050;
vicilin/0.062; legumin B chain/0.061 total=20
Opioid aS1-casein/0.027; b-casein/0.009; a-lactalbumin/0.021; b-lactoglobulin/0.006; k-casein/0.016; a1-colla-
gen/0.001; troponin C/0.006; egg ovalbumin/0.010; a/b-gliadin precursor/0.012; a-hordothionin




b-casein/0.029; a1-collagen/0.267; 12S seed storage globulin precursor/0.006; 7S globulin precursor/0.006;
11S cruciferin/0.008; phaseolin, b-type/0.002; vicilin/0.007; legumin B chain/0.003 total=8
Regulation of ion
flow
b-lactoglobulin/0.006; carp parvalbumin/0.009; a-hordothionin precursor/0.008; phaseolin, b-type/0.002;
vicilin/0.002 total=5
Other activities*: antibacterial (1), coeliac-toxic (1), chemotactic (1), contracting smooth muscles (1), neuropeptide (1), stimulating
g-interferon production (1), embryotoxic (2), regulating phosphoinositole mechanism (3)
*Other activities revealed in some of the analyzed proteins. The numbers in parentheses indicate the total number of the protein se-
quences in which the given activity was found
and stimulating g-interferon production occurred only in
a-lactalbumin, a/b-gliadin precursor (coeliac-toxic and
stimulating g-interferon production), a1-collagen, k-case-
in and b-lactoglobulin, respectively. The relatively low
values of A calculated for these activities reflect their
small number of fragments (maximum 3) that occur in
the proteins, which it is an obstacle when discussing the
structural character of the motif in the context of its bio-
activity. The highest value of A (0.244) among the above-
-mentioned activities was obtained for coeliac-toxic activ-
ity in the a/b-gliadin precursor. Some grain proteins,
including wheat, possess motifs that initiate pathophys-
iological processes, which are a factor affecting intestinal
epithelial damage. Wheat gliadins contain fragments re-
leased during the protein digestion and lead to coeliac
disease. These fragments have characteristic amino acids
such as proline, tyrosine and glutamine, responsible for
coeliac disease and they are primarily located in the N-ter-
minal domain of the gliadin chain (22).
All twenty analyzed protein sequences showed the
presence of ACE and dipeptidyl peptidase-IV (DPP-IV)
inhibitors. Motifs with the ACE inhibitory activity are
the best represented group among the sequences of food
proteins (23). BIOPEP analysis revealed that the best pre-
cursor of ACE inhibitors can be bovine collagen with the
A value of 0.874. It is due to the length of the chain and
the higher probability of the occurrence of bioactive mo-
tif. ACE peptide inhibitors were identified in many food
raw materials and products such as fish, milk proteins
and cereals (24). Milk proteins derived from different spe-
cies are a rich source of ACE inhibitors (25,26). Iwaniak
and Dziuba (2) compared the profiles of potential ACE
inhibitory activity of milk proteins and revealed the pre-
sence of many fragments with such an activity (e.g. from
45 in case of bovine a-lactalbumin to 121 in genetic va-
riant B of b-casein). The impact of the structure of ACE
inhibitors on their activity depends on the C-terminal ami-
no acid residue. The presence of tyrosine (Tyr), phenyl-
alanine (Phe), tryptophan (Trp) and proline (Pro) at the
C-terminus of a peptide contributes to its higher activity.
Tryptophan exerts the strongest influence on the ACE
inhibitory activity of peptides. The conformation of the
peptide is also an important factor affecting the efficien-
cy of the interactions of ACE inhibitors (25).
Dipeptidyl peptidase-IV (DPP-IV) inhibitors were re-
vealed in all analyzed proteins. DPP-IV (EC 3.4.14.5) is
an enzyme belonging to the serine proteases (27) and is
responsible for the breakdown of glucagon-like peptide
(GLP-1) and gastric inhibitory polypeptide (GIP). Inhi-
bition of DPP-IV prolongs the in vivo half-life of GLP-1
and GIP, leads to the enhancement of insulin secretion
and improves glucose tolerance, which makes DPP-IV
inhibitors valuable in treating type 2 diabetes (27,28). Food
containing proteins with DPP-IV inhibitors could repre-
sent a good diet for patients suffering from diabetes. The
best sources of peptides with this activity were b-casein,
a1-collagen and myosin (A values were: 0.148, 0.268 and
0.112, respectively).
All twenty sequences taken for analysis that showed
the presence of fragments with the above-mentioned ac-
tivities, i.e. inhibitors of ACE as well as DPP-IV, can be
found in BIOPEP. Generally, peptides in the BIOPEP data-
base described as 'inhibitors' are the most numerous (671
in total). Currently, the number of ACE inhibitors (pep-
tides involved in blood pressure reduction) is 530 and
DPP-IV inhibitors is 11. The remaining 130 peptides list-
ed in the database concern other kinds of inhibitors which
were not found in the sequences of proteins taken for
analysis.
Although the BIOPEP database contains only eleven
motifs acting as dipeptidyl peptidase-IV inhibitors (com-
pared to the number of ACE inhibitors), they occurred
in all the analyzed proteins because of the structural simi-
larities between them and ACE inhibitors. The similarity
relied on the occurrence of proline residues in the se-
quences of ACE and DPP-IV inhibitors. As described
above, proline is one of the crucial amino acid residues
involved in ACE inhibitory activity (25) and also it seems
important in DPP-IV inhibitory activity. Most DPP-IV
inhibitors are called proline-like compounds (27).
The in silico studies showed that all food-derived
protein sequences can be a potential source of peptides
responsible for the ubiquitin-mediated proteolysis (see
Table 2). Proteins are mainly a source of amino acids,
which are essential for cell maintenance and growth of
human body (29). Due to the ageing processes or other
factors affecting their proper functioning, these proteins
can cause serious damage. A small molecule peptide
called ubiquitin recognizes such proteins and controls the
process of their degradation (30). Ubiquitin is a 76-re-
sidue polypeptide which exists in all eukaryotic cells. The
characteristic motif of this protein is seven lysine resi-
dues at the C-terminus. The C-terminal glycine of ubi-
quitin is activated by ATP to a high-energy intermediate
during a reaction catalyzed by a ubiquitin-activating en-
zyme (31). Research on ubiquitin-mediated proteolysis can
lead to a better understanding of the pathogenesis of neu-
ral diseases such as Alzheimer's or Parkinson's (32) as
well as elucidation of the mechanism of regulation and
degradation of specific proteins defined as oncoproteins
(31).
Twelve proteins possessed motifs with anti-amnestic
activity. Peptides with this activity are prolyl endopep-
tidase (PEP) inhibitors (33). They are involved in learn-
ing and memory abilities and are found in food pro-
teins, e.g. corn and rice. A typical motif for inhibitors of
prolyl endopeptidases is repetitive proline residue (34).
The highest value of frequency of the occurrence of anti-
-amnestic fragments was obtained for bovine collagen
(A=0.267). This protein is built up from 779 residues, with
many prolines that match the sequences of PEP inhibi-
tors (anti-amnestic peptides).
The frequency of the occurrence of fragments with
antioxidative activity was obtained for 11 protein sequen-
ces. The values of this parameter were relatively low (the
highest value of A=0.014 was for b-casein). The main com-
ponents of the antioxidative peptides derived from dif-
ferent proteins are mainly the amino acids known for
their antioxidative properties, such as histidine or tyro-
sine. Similar properties can also be assigned to methio-
nine, lysine and tryptophan. The activity of these pep-
tides affects their primary structure as well as configuration
(34). The presence of hydrophobic residues fosters the
interaction of peptides with linoleic acid and the num-
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ber of prolines (the more, the better) contributes to an
increase in the antioxidant activity of the peptide (34).
Bovine collagen was the best source of peptides with
antithrombotic activity (A=0.298) amongst the 10 protein
sequences, which also contained fragments with the above-
-mentioned activity. The effect of peptides derived from
porcine skin collagen on fibrin polymerization and plate-
let aggregation was studied by Nonaka et al. (35,36).
They found that peptides with the G-protein regulatory
(GPR) motif, including their analogues such as GPRG,
GPRGP, GPRPP and GPRPPP, suppressed the platelet
aggregation in humans. The occurrence of proline and
glycine is typical for fragments with an anticoagulant
effect. These amino acid residues are present in the C-ter-
minal sequence of fibrin a-chain and are responsible for
its polymerization. One of the milk proteins – casein – is
also known as a good source of anticoagulant fragments.
In this study, b- and k-casein had relatively high values
for the frequency of the occurrence of antithrombotic frag-
ments (A=0.029 and A=0.021, respectively). The presence
of motifs with antithrombotic activity results from the
fact that k-casein and g-fibrin evolved from a common
ancestor. This is confirmed by the similarities in the mech-
anisms of chymosin-induced milk and thrombin-induced
blood coagulation (37).
Twelve proteins (of all twenty studied) showed the
presence of peptides which are ligands of bacterial per-
meases. Oligopeptide permeases are responsible for the
uptake of peptides in some species of bacteria and ar-
chaea. These permeases are involved in many processes
such as: cell wall synthesis, adhesion to host cells and
proteins, gene regulation of intercellular signalling, com-
petence development and sporulation. One of the compo-
nents of oligopeptide permease is periplasmic peptide-bind-
ing component (OppA). OppAs can bind oligopeptides
of different sizes: from three (e.g. Salmonella typhimurium
OppA orthologues) to eighteen (e.g. Lactococcus lactis OppA
paralogues). The binding activity of OppAs of bacterial
species may affect cell envelope permeability restrictions
and the nutritional strategy required for survival in a spe-
cific environment (38).
The majority of proteins (fourteen out of twenty)
shown in Table 2 were relatively rich in opioid frag-
ments. According to Meisel and FitzGerald (39), many
opioid peptides are very potent – even insignificant
amounts of released peptides exert a physiological effect.
Opioid peptides are rich in tyrosine. Tyr is the charac-
teristic residue for endogenous opiates such as enkepha-
lin, dynorphin and endorphin. They all possess a YGGF
motif located in the N-terminal part of the chain (35).
The presence of Tyr and Phe at the third or fourth po-
sition fits to the binding sites of opioid receptors. Re-
moval of tyrosine is the cause of the lack of bioactivity
(39). The presence of proline at the second position fa-
vours opioid activity due to the maintenance of the prop-
er orientation of the Pro- and Tyr-side chains (39).
Some peptides possess several bioactivities. For ex-
ample, glycylproline peptides (peptides assigned to the
glyproline family) are responsible for antithrombotic ef-
fects and the protection of gastric mucosa against vari-
ous ulcerogenic factors as well as having some anorectic
actions (38). Eight proteins, i.e. b-casein; a1-collagen; 12S
seed storage globulin precursor; 7S globulin precursor;
11S cruciferin; phaseolin, b-type; vicilin and legumin B
chain showed the presence of motifs with an activity de-
fined as the regulation of stomach mucosa membrane.
The above-mentioned proteins appear to be a source of
antithrombotic peptides (see Table 2). According to Sa-
monina et al. (40), glyprolines can be formed from the
precursors like collagen and elastin. Peptides with regu-
latory activities are usually liberated from specialized pre-
cursors, but there is data concerning their formation from
various unspecific precursors (40). The bioactivity of pep-
tides derived from specific precursors are active in very
low concentrations (the highest floor), and those derived
from non-specific sources have moderate bioactivity (the
lowest floor). Such division of regulatory peptides was
described as the 'multi-floor peptide regulatory system'
by Karelin et al. (41).
Some of the analyzed proteins showed that they could
be a potential source of peptides with immunomodulat-
ing effect and for regulation of ion flow. Peptides with
immunomodulating activity occurred in milk proteins as
well as in a-collagen and b-phaseolin. The values of fre-
quency of the occurrence of fragments with immunomo-
dulating activity for milk proteins were relatively low
(from 0.005 to 0.021). The best source of these fragments
was phaseolin (A=0.312). Peptides regulating ion flows
were observed only in six proteins and the A values for
this activity were low. The explanation is that BIOPEP
contains only two peptides with this activity. Based on
such limited information concerning the peptides that reg-
ulate ion flow, it is hard to discuss the structural re-
quirements of their bioactivity.
Fig. 2 shows the distribution of the individual sec-
ondary structures performed for the BIOPEP-generated
protein sequences by means of the PBIL server (12). The
secondary structures of proteins were predicted by the
GOR (Garnier-Osguthorpe-Robson) method (42). The GOR
algorithm combines both information theory and Baye-
sian statistics for predicting the secondary structure of a
molecule (43).
As mentioned above, all analyzed proteins revealed
the presence of the inhibitors of angiotensin-converting
enzyme (ACE) and dipeptidyl peptidase-IV (DPP-IV).
Great majority of these peptides matched the random
coiled part of the protein chains. Based on the profiles of
potential biological activity of proteins (see Materials and
Methods), in the case of the porcine troponin C, most of
the ACE inhibitors were situated in the a-helical struc-
ture of the protein (over 30 fragments), and a coil was
revealed in fourteen peptides matching this structure. In
the case of the structure of DPP-IV inhibitors – their struc-
ture was more diversified. In nine out of twenty pro-
teins, peptides had a random coil structure (b- and k-ca-
seins, collagen, globulins 12S and 7S from oat and soy-
bean, rapeseed cruciferin, kidney bean phaseolin, garden
pea vicilin and fava bean legumin). A combination of
helices and coils appeared in peptides present in a-lact-
albumin, b-lactoglobulin, chicken myosin, porcine tropo-
nin, carp and salmon parvalbumins, egg cystatin and oval-
bumin, and a/b-wheat gliadin. DPP-IV inhibitors found
in a-casein and barley hordothionin were a combination
of coils, extended strands and a-helices.
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Almost all protein sequences (see Table 2), exclud-
ing b-casein and b-parvalbumin, can be regarded as a
potential source of fragments activating ubiquitin-medi-
ated proteolysis. They were located in the parts of the
protein chains containing a-helix, random coils and ex-
tended strands. The frequency of the occurrence of frag-
ments possessing this bioactivity (A) was from 0.005 for
a-casein to 0.018 for fava bean legumin. The value of A
calculated for specific bioactivity depends on the num-
ber of peptides gathered in the BIOPEP database (the
smaller number of peptides, the lower the value of A).
BIOPEP database contains only three peptides that are
responsible for the activation of ubiquitin-mediated pro-
teolysis (RA, LA, WA) and that may explain the rela-
tively small values of frequency of the occurrence of frag-
ments with the above-mentioned activity. The existence
of a small number of these peptides in the proteins, as
well as their random occurrence in them (from one to a
maximum of three in the whole protein chain) does not
provide any clues as to which type of the peptide struc-
ture might be responsible for the activation of ubiquitin-
-mediated proteolysis (due to the 'coincidental' locations
of the peptides in different structures of the protein chains).
The same line of reasoning could be applied to all pro-
teins found as precursors of peptides defined as bacte-
rial permease ligands (three of them in the BIOPEP; their
sequences are: KK, KKK, KKKA), regulators of ion flow
(two peptides in BIOPEP: DY and TSLYR), and regula-
tors of phosphoinositole mechanism (five peptides in BIO-
PEP: GFW, GFL, LGY, GLY and GLF) (16).
Different types of structures were found in fragments
with opioid and antibacterial activities, or with mecha-
nisms of ion flow and phosphoinositole regulation. In
the case of opioid and antibacterial effects of peptides
present in some of the analyzed proteins, their number
in BIOPEP was high enough (158 and 419, respectively)
to discuss the structure and bioactivity relationship. How-
ever, some of them were built up from e.g. 17 (YGGFL-
RARKSARKLANQ) to 34 amino acid residues (GICAC-
RRRFCPNSERFSGYCRVNGARYVRCCSRR) or occurred
as C-terminal amides, which presented an obstacle in
matching the protein sequence for identification accord-
ing to the profile of the potential biological activity of
the protein (16,20).
The information obtained from BIOPEP using PBIL
concerning the bioactivities of peptides related to parti-
cular secondary structures of the proteins is summar-
ized in Table 3. Peptides which represent one activity
were first summarized and then put in three groups oc-
cupying one of the three secondary structures. The mean
percentages of peptides matching the individual second-
ary structure were then calculated for all peptide activ-
ities.
Some of the biopeptides completely matched the ran-
dom coil parts of the precursor protein chain (Table 3).
These fragments represented the following activities: anti-
amnestic, antithrombotic, coeliac-toxic, responsible for the
action of stomach mucosa membrane, chemotactic, neuro-
peptide, stimulating production of g-interferon, involved
in the smooth muscle contraction and embryotoxic activ-
ities. Fragments representing the last five activities ap-
peared in one or a maximum of two proteins and the
maximum number of peptides present in these proteins
ranged from one to three. Coeliac-toxic peptides were iden-
tified only in a/b-wheat gliadin precursor (over sixty of
them). Although coeliac-toxic peptides are relatively long,
they possess some common motifs such as proline and
glutamine – amino acids that are repetitive in the whole
protein sequence and are mostly located in the coiled
structure of wheat gliadin. Antiamnestic, antithrombotic
and immunomodulating fragments which fully matched
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Table 3. The level of structural matching of peptides calculated




































































































































































*number of peptides found in the particular structure of the pro-
tein chain
the coiled structure were relatively short with repetitive
prolines and glycines. This suggests the probability of
their frequent occurrence in the appropriate protein struc-
ture. This rule can be applied to ACE and DPP-IV inhibi-
tory activity (1700 and 499 of peptides in total, respec-
tively, were random-coil dominated).
When discussing the secondary structures of frag-
ments with specific activity, particular attention should
be paid to the length of the peptide chain. Many of bio-
active peptides are short sequences (di- or tripeptides)
(25). Knowing the fact that one of the major secondary
structures of proteins, a-helix, requires 3.6 amino acids
per one turn of a helical chain (44), it should be noted
that defining the structure matching the short peptides
means locating them in a longer fragment possessing a
particular structure or at the border of fragment match-
ing different structures. However, an analysis of the struc-
ture of bioactive motifs by means of BIOPEP combined
with PBIL can be a useful strategy to look for some
structural requirements determining the bioactivity of pep-
tide(s).
To conclude, a structural analysis of peptides repre-
senting a variety of bioactivities showed that bioactive
motifs mostly occupy random coil or helical parts of the
protein chain. Some of the peptides matched a combi-
nation of coil and helix structures. These peptides were
rich in proline or aromatic residues, which also seems to
be crucial in the context of the structure-activity relation-
ship of peptides.
Conclusions
The BIOPEP and Pôle Bioinformatique Lyonnais anal-
ysis tools provide valuable data on food protein precur-
sors as a source of bioactive peptides combined with the
structural aspects of bioactivities encrypted in proteins.
The most recent analysis of food proteins has found that
they could be a source of peptides affecting neural di-
seases (e.g. ubiquitin-mediated proteolysis peptides). This
could be significant in terms of the relations between the
diet and the health of potential patients. The structure-
-bioactivity relationship of peptides analyzed via the meth-
od involving the BIOPEP-Pôle Bioinformatique Lyonnais
server showed that in order to be bioactive, it is essen-
tial for peptides to assume the position of a coil (or a
combination of coil and a-helix) in the sequence of their
protein precursors. However, it should be noted that the
number of peptides in the data resources (databases), the
length of the peptide chain and the repeatability of the
occurrence of characteristic motifs (i.e. amino acids), both
in the peptide and in the protein, affect the accuracy of
studies of the bioactivity of molecules.
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